Building on its groundbreaking work in Oculomics, UK MedTech innovator Occuity is now moving from concept to commercial success, turning its patented optical platform into real products, revenue and global partnerships.
Founded with a mission to make health screening and disease monitoring simpler, faster and pain free, Occuity’s technology uses light to scan through the eye and analyse the reflections returned. This enables clinicians to take precise measurements or identify early biomarkers of disease without ever touching the eye.
Real products, real markets
Occuity’s first device, the PM1 Pachymeter, is now CE Marked and commercially available and generating revenue through a growing global network of 19 distributors. The PM1 enables fast, contact-free measurement of corneal thickness, a key parameter in the screening and management of glaucoma, one of the leading causes of blindness worldwide.
Building on that success, the company is advancing development of its next device, the AX1 Axiometer, designed for use in the rapidly expanding myopia management market, forecast to reach US $11.7 billion by 2030. With myopia soon to be affecting around half of the global population, the AX1 aims to provide eye-care professionals with a simple, handheld device for measuring axial length – the key biomarker in managing short-sightedness.
A scalable platform for growth
What sets Occuity apart is that all of these devices are built upon the same optical platform described in the company’s earlier feature. This shared foundation allows faster product development, more efficient regulatory pathways and a sustainable commercial model. Each new device strengthens the platform, widening its application across ophthalmology and systemic disease detection.
This platform approach is key to Occuity’s long-term strategy, providing opportunities not only for device sales but also for future data-driven insights and diagnostics that could transform healthcare delivery.
Global reach and strong IP
Occuity’s technology has already attracted international attention, with partnerships across Europe, the Middle East and Asia. Its 15 patent families – covering optical design, scanning systems and alignment methods – create significant barriers to entry and reinforce its competitive edge.
As CEO Dan Daly explains:
“Our goal has always been to make advanced diagnostic technology more accessible. The PM1 and AX1 are just the beginning. The same core technology will power our future devices for diabetes and Alzheimer’s, helping clinicians identify disease earlier, faster and without pain or inconvenience.”
Building momentum and investor confidence
Occuity’s transition from R&D to commercial traction comes at a pivotal time. With its Republic Europe crowdfunding campaign now live, investors have the opportunity to back a company that has proven its technology, established early revenue and built a clear roadmap to scale.
For those seeking exposure to global healthcare markets and the growing field of Oculomics, Occuity offers a compelling combination of innovation, defensibility and purpose.
With its crowdfunding campaign live on Republic, if you’re looking for an ethical investment opportunity which offers exciting potential returns, you can learn more about Occuity here.
Disclosure: This article is for information only and does not constitute investment advice. Capital is at risk.